87 related articles for article (PubMed ID: 7512081)
1. Antigenicity of three synthetic peptides from the C-terminus of HIV-1 gp 120 correlates with the fragmentation pattern obtained in FAB mass spectrometry.
Streckert HJ; Weber C; Müller D
Intervirology; 1993; 36(3):128-33. PubMed ID: 7512081
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of synthetic peptides corresponding to various epitopes of the human immunodeficiency virus envelope protein.
Zaghouani H; Hall B; Shah H; Bona C
Adv Exp Med Biol; 1991; 303():53-62. PubMed ID: 1725238
[No Abstract] [Full Text] [Related]
3. Effect of sialic acid removal on the antibody response to the third variable domain of human immunodeficiency virus type-1 envelope glycoprotein.
Benjouad A; Mabrouk K; Gluckman JC; Fenouillet E
FEBS Lett; 1994 Mar; 341(2-3):244-50. PubMed ID: 8137947
[TBL] [Abstract][Full Text] [Related]
4. CD4+ T-lymphocyte lines developed from HIV-1-seropositive patients recognize different epitopes within the V3 loop.
Ratto S; Sitz KV; Scherer AM; Loomis LD; Cox JH; Redfield RR; Birx DL
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Feb; 11(2):128-36. PubMed ID: 8556394
[TBL] [Abstract][Full Text] [Related]
5. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.
Dis Markers; 1991; 9(1):51. PubMed ID: 1742945
[No Abstract] [Full Text] [Related]
6. Epitope mapping and topology of baculovirus-expressed HIV-1 gp160 determined with a panel of murine monoclonal antibodies.
Abacioglu YH; Fouts TR; Laman JD; Claassen E; Pincus SH; Moore JP; Roby CA; Kamin-Lewis R; Lewis GK
AIDS Res Hum Retroviruses; 1994 Apr; 10(4):371-81. PubMed ID: 8068416
[TBL] [Abstract][Full Text] [Related]
7. Computer predictions of antigenic domains in human immunodeficiency virus-1 envelope glycoprotein: comparison with reported experimental data.
Becker Y
Virus Genes; 1990 Apr; 3(4):323-41. PubMed ID: 1693457
[TBL] [Abstract][Full Text] [Related]
8. Comparison and fine mapping of both high and low neutralizing monoclonal antibodies against the principal neutralization domain of HIV-1.
Langedijk JP; Back NK; Kinney-Thomas E; Bruck C; Francotte M; Goudsmit J; Meloen RH
Arch Virol; 1992; 126(1-4):129-46. PubMed ID: 1381908
[TBL] [Abstract][Full Text] [Related]
9. High-titer HIV-1 neutralizing antibody response of rhesus macaques to gp160 and env peptides.
Ronco J; Dedieu JF; Marie FN; Pinter A; Kaczorek M; Girard M
AIDS Res Hum Retroviruses; 1992 Jun; 8(6):1117-23. PubMed ID: 1503824
[TBL] [Abstract][Full Text] [Related]
10. Biological properties of recombinant HIV envelope synthesized in CHO glycosylation-mutant cell lines.
Fenouillet E; Miquelis R; Drillien R
Virology; 1996 Apr; 218(1):224-31. PubMed ID: 8615025
[TBL] [Abstract][Full Text] [Related]
11. Epitopes at the proteolytic cleavage sites of HIV-1-gp120 and RSV-F protein share a sequence homology: comparative studies with virus-induced and antipeptide antibodies.
Streckert HJ; Werchau H
Intervirology; 1992; 34(1):30-7. PubMed ID: 1385356
[TBL] [Abstract][Full Text] [Related]
12. Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants.
Li Y; Svehla K; Mathy NL; Voss G; Mascola JR; Wyatt R
J Virol; 2006 Feb; 80(3):1414-26. PubMed ID: 16415019
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and epitope mapping of a recombinant soluble gp160 of the human immunodeficiency virus type 1 envelope glycoprotein.
Pasquali JL; Kieny MP; Kolbe H; Christmann D; Knapp AM
AIDS Res Hum Retroviruses; 1990 Sep; 6(9):1107-13. PubMed ID: 1702300
[TBL] [Abstract][Full Text] [Related]
14. Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein.
Gao F; Weaver EA; Lu Z; Li Y; Liao HX; Ma B; Alam SM; Scearce RM; Sutherland LL; Yu JS; Decker JM; Shaw GM; Montefiori DC; Korber BT; Hahn BH; Haynes BF
J Virol; 2005 Jan; 79(2):1154-63. PubMed ID: 15613343
[TBL] [Abstract][Full Text] [Related]
15. Antigenicity of linear and cyclic peptides mimicking the disulfide loops in HIV-2 envelope glycoprotein: synthesis, reoxidation and purification.
Belhadj Jrad B; Bahraoui E
J Pept Res; 1998 May; 51(5):370-85. PubMed ID: 9606017
[TBL] [Abstract][Full Text] [Related]
16. Improbability of harmful autoimmune responses resulting from immunization with HIV-1 envelope glycoproteins.
Neurath AR; Strick N; Li YY; Jiang S
AIDS Res Hum Retroviruses; 1993 Dec; 9(12):1195-208. PubMed ID: 8142138
[TBL] [Abstract][Full Text] [Related]
17. Characterization of a soluble, oligomeric HIV-1 gp160 protein as a potential immunogen.
VanCott TC; Veit SC; Kalyanaraman V; Earl P; Birx DL
J Immunol Methods; 1995 Jun; 183(1):103-17. PubMed ID: 7602128
[TBL] [Abstract][Full Text] [Related]
18. Adjuvanticity of stearyl tyrosine on the antibody response to peptide 503-535 from HIV gp160.
Nixon A; Zaghouani H; Penney CL; Lacroix M; Dionne G; Anderson SA; Kennedy RC; Bona CA
Viral Immunol; 1992; 5(2):141-50. PubMed ID: 1616585
[TBL] [Abstract][Full Text] [Related]
19. Immunogenic and antigenic properties of an HIV-1 gp120-derived multiple chain peptide.
Kelker HC; Schlesinger D; Valentine FT
J Immunol; 1994 Apr; 152(8):4139-48. PubMed ID: 8144976
[TBL] [Abstract][Full Text] [Related]
20. Immunological analysis of human immunodeficiency virus type 1 envelope glycoprotein proteolytic cleavage.
Fenouillet E; Gluckman JC
Virology; 1992 Apr; 187(2):825-8. PubMed ID: 1372142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
